Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: Approvals For Xultophy, Soliqua And Darzalex; NDAs From Intarcia And GSK; Complete Response For Green Cross

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker

You may also be interested in...



Keeping Track: Scenesse, Reyvow, and Beovu Make Trio Of Novel Approvals

The latest drug development news and highlights from our US FDA Performance Tracker.

Keeping Track: A Lilly Breast Cancer Approval, A Couple Of CRLs, And A Plethora Of Priority Reviews

The latest drug development news and highlights from our Performance Tracker.

Boehringer Aims To Block GSK's Triple COPD Inhaler, Citing Combo Rule

GSK's triple COPD combo needs Phase III trial using comparators with same active ingredients and applying factorial design, BI contends in citizen petition to US FDA.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel